Limb and CNS expressed 1 like (LIX1L)

Limb and CNS expressed 1 like (LIX1L) is a **protein-coding gene** located on chromosome 1q21.1 that encodes a **putative RNA-binding protein** with a predicted double-stranded RNA-binding motif[1][2][3][7]. LIX1L is most notable for **promoting cancer cell proliferation** and inhibiting apoptosis, with its expression increased in a wide variety of cancers (e.g., esophageal, gastric, breast, lung, ovarian, pancreatic, etc.)[1]. The protein interacts with other RNA-binding proteins and several miRNAs, suggesting a role in post-transcriptional regulation[1]. Functional studies indicate that LIX1L knockdown leads to suppressed cell proliferation and increased apoptosis, supporting its role as an oncogenic factor[1]. It is also predicted to participate in autophagosome maturation and is broadly expressed in the central nervous system and peripheral tissues[2][4][5]. Targeting LIX1L (e.g., with mimetic peptides that block key phosphorylation sites) can inhibit cell proliferation in cancer cell lines, indicating its potential as a **therapeutic target**, though no drugs are currently approved for this indication[1].

Other names

LIX1-like proteinLIX1 homolog-likeMGC46719LIX1L proteinLix1l

None established for direct pharmacological targeting; experimental peptides (e.g., PY136) can inhibit LIX1L phosphorylation and proliferation in cancer cells[1]